Ketogenic diet therapy yields 42.82% seizure reduction in drug-resistant epilepsyKetogenic Diet Therapy Shows Promise for Drug Resistant Epilepsy
SeizurePublished August 7, 2026Study authors: Farrar Tania, D'Silva Arlene, Cardamone Michael, Palacios-Derflingher Luz, Farrar Michelle APubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider ketogenic diet therapy as adjunctive treatment for drug-resistant epilepsy, especially generalized types, but weigh attrition risk.
This meta-analysis pooled data from 1019 adolescents and adults with drug-resistant epilepsy to evaluate the association between ketogenic diet therapy (KDT) and seizure control. The primary outcome was the proportion of individuals achieving greater than 50% seizure reduction. The overall rate was 42.82% (95% CI 34.14-51.69).
Subgroup analyses revealed a higher rate in individuals with generalized drug-resistant epilepsy (53.4%, 95% CI 16.92-88.20) compared to those with focal drug-resistant epilepsy (14.4%, 95% CI 0.00-42.25). The wide confidence intervals, particularly in the focal group, indicate considerable uncertainty.
The authors note that KDT was generally well tolerated, but attrition due to restrictiveness and compliance challenges was 20.95%. The meta-analysis included RCTs, prospective, and retrospective case series, and the association between KDT and seizure reduction should not be interpreted as causal. Efficacy was not found to be associated with KDT type.
The findings support considering KDT as an adjunctive treatment for some individuals with drug-resistant epilepsy, particularly those with generalized epilepsy. However, the high attrition rate and heterogeneity across studies warrant cautious interpretation. The results are relevant for guideline development and optimizing management, but further research is needed to clarify patient selection and long-term outcomes.
How this fits prior evidence
This meta-analysis extends prior coverage on epilepsy management by quantifying the potential benefit of ketogenic diet therapy in drug-resistant epilepsy, a population not addressed in earlier items. While previous items focused on educational programs, antiseizure medication withdrawal, and surgical options, this synthesis adds dietary therapy as another adjunctive strategy. The 42.82% response rate aligns with the modest efficacy seen with other interventions, and the higher response in generalized epilepsy mirrors patterns noted in clinical practice. However, the 20.95% attrition rate highlights tolerability challenges, contrasting with the more definitive outcomes reported for MRgLITT and open resection.
Researchers analyzed data from 1,019 people with drug resistant epilepsy to see how a ketogenic diet therapy (KDT) affected their symptoms. This type of study combines several different reports to find broader patterns in how the treatment works for patients who do not respond well to standard medications.
The results showed that about 42.82 percent of all participants experienced a reduction in seizures of more than 50 percent. For those with generalized drug resistant epilepsy, the success rate was higher at 53.4 percent. However, only 14.4 percent of people with focal drug resistant epilepsy saw this same level of improvement.
While the diet is generally well tolerated by patients, it can be hard to maintain. About 20.95 percent of people stopped the treatment because the rules were too strict or difficult to follow. This evidence suggests that while the ketogenic diet can be a helpful extra treatment for some people with drug resistant epilepsy, its success may depend on the specific type of epilepsy a person has.
What this means for you:
A ketogenic diet can reduce seizures by over 50 percent in about half of patients with generalized drug resistant epilepsy.
Common questions
How effective is the ketogenic diet for different types of epilepsy?
The effectiveness varies based on the type of condition. The study found that 53.4 percent of people with generalized drug resistant epilepsy saw a seizure reduction of over 50 percent. In contrast, only 14.4 percent of those with focal drug resistant epilepsy experienced that same level of improvement.
Is the ketogenic diet easy for patients to follow?
The treatment is generally well tolerated by most people. However, it can be difficult to maintain because of its strict requirements. The study reported that about 20.95 percent of participants stopped the therapy due to challenges with compliance and the restrictive nature of the diet.
Who is this treatment intended for?
This treatment is specifically looked at for adolescents and adults who have drug resistant epilepsy. It is considered an adjunctive treatment, meaning it is used alongside other treatments to help manage symptoms when standard medications are not enough.
Ketogenic diet therapy (KDT), characterised by its high-fat, low-carbohydrate composition, is a valuable approach to reducing seizures in children with drug resistant epilepsies (DRE). Uncertainty remains regarding its benefits in adolescents and adults. This systematic review and metanalysis critically evaluated evidence efficacy, safety and tolerability of KDT in adolescents and adults with DRE. Analysis was also undertaken on epilepsy and KDT subtypes, side effects, attrition proportions and reasons for KDT cessation, along with effects beyond seizure control including mood and quality of life outcomes. Of the 1846 articles screened, 33 met the inclusion criteria, 3 randomised controlled trials, 17 prospective and 13 retrospective case series and included 1019 people with DRE. The overall proportion with seizure reduction >50 % was 42.82 % (95 %CI 34.14-51.69). Subgroup analysis suggested that 53.4 % (95 %CI: 16.92-88.20 of individuals with generalised DRE responded to KDT, compared to 14.4 % (95 %CI: 0.00-42.25) with focal DRE. The efficacy was not found to be associated with KDT type. Restrictiveness and compliance challenges led to an overall attrition proportion of 20.95 % (95 %CI 12.06-31.19). Findings suggested that KDTs were safe and generally well tolerated. Taken together, there is increasing evidence to support use of KDT as an adjunctive treatment for some people with DRE. The knowledge generated is pertinent to establishing guidelines, optimising the use of KDT in specific epilepsy populations to improve therapeutic management.
